Medicare to Cover Clinical Trial Costs
June 7, 2000 (Washington) -- Medicare will immediately begin covering the routine care costs for seniors and the disabled in clinical trials, President Clinton announced Wednesday in a special executive memorandum. Clinton's move is intended to encourage senior enrollment in clinical trials, which may speed progress toward disease treatments and cures.
Only about 1% of the nation's seniors participates in clinical trials, even though they suffer the brunt of the nation's diseases, according to administration documents.
This week, the Health Care Financing Administration (HCFA) will inform physicians, hospitals, and other providers that it will reimburse standard costs, including hospital and physician visits and routine lab tests, as well as those costs that are due to medical complications associated with participation in trials.
Although the sponsors of clinical studies usually pick up the costs of experimental agents and therapies, Medicare policies on the coverage of standard care delivered to patients while in trials have been unclear. That has presented potential trial enrollees with the unattractive option of paying out-of-pocket for expenses that would otherwise be covered.
The cost question is a barrier to enrollment in clinical trials, according to a survey discussed at the annual meeting of the American Society of Clinical Oncology held in May.
Some 63% of cancer patients are older than 65, but they constitute only 33% of those enrolled in clinical trials. For breast cancer patients, the statistics are even worse. Women over 65 make up 44% of breast cancer patients, but less than 2% of elderly women are in clinical trials for the condition.
According to the White House, the low participation in clinical trials means "scientists often need between three and five years to enroll enough participants in a clinical trial to generate ? meaningful results" that could lead to improvements in diagnosing and treating diseases.
Robert Comis, MD, president of the Coalition of National Cancer Cooperative Groups, calls Clinton's announcement "tremendous news." He tells WebMD, "We've been making a lot of progress on the private side, but HCFA has been the last frontier -- probably the greatest threat to the clinical trials process."